ClinicalTrials.gg
RecruitingNCT07375914CALM-EDUpdated Oct 8, 2026

Comprehensive Biopsychosocial Approach for Acute Low Back Pain Management in the Emergency Department: a Stepped-wedge Cluster-randomized Clinical Trial

An interventional study of Biopsychosocial intervention in Non-traumatic Low Back Pain, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
782
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Low Back Pain by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 3 of them phase 3. Low Back Pain · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 17
782 · median 130
Started
2026
with 4 others
No phase
12 of 20
6 open now
Registered
19th of 20
by date

Among the 20 studies in Low Back Pain by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is one of 12 with no phase, and was the 19th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

9 of the 20 studies in Low Back Pain by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Low Back Pain by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Acute low back pain, the second leading cause of medical consultations in France, poses a major public health challenge, particularly because of its high risk of progressing to chronic low back pain-the leading cause worldwide of years lived with disability. Pharmacological treatments such as paracetamol, opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants show limited benefit in terms of pain intensity or functional disability. Non-pharmacological treatments, including exercise therapy and psychological support, show promising results but remain hampered by methodological biases and small sample sizes.

A biopsychosocial approach that combines pharmacological treatments, physical therapy, psychological support and social interventions has demonstrated moderate improvements in pain and function for chronic low back pain but remains insufficiently studied for acute presentations. French guidelines advocate a combined strategy involving paracetamol, NSAIDs, physical activity and psychosocial risk assessment. However, a French multicentre retrospective study highlighted marked heterogeneity in clinical practice, along with a low adoption rate (\<10 %) of these recommendations in emergency departments, underscoring the need to strengthen adherence to evidence-based management strategies. We hypothesise that a multimodal intervention targeting physicians (guideline reminders) and patients (information on disease progression and multidisciplinary care plans), to enable the systematic implementation of all aspects of a biopsychosocial approach in emergency departments, could reduce short-term pain and disability in patients with acute low back pain.

03

Conditions studied

  • Non-traumatic Low Back Pain

Browse trials for

Keywords

  • Emergency medicine
  • Acute Low back pain
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 55 presenting to a participating emergency department, and
  • Presenting with acute non-traumatic low back pain, newly developed or worsened within the past 7 days.
  • Moderate to severe pain, defined as a score of ≥4 on a 0-10 numerical rating scale.
  • Provision of after being given the information sheet.
  • Patients covered by social security (excluding AME).

Exclusion criteria

Exclusion Criteria:

  • Presence of a 'red flag' according to HAS guidelines, including: motor neurological deficit or cauda equina syndrome, non-mechanical pain, trauma, active neoplastic disease or history of inflammatory rheumatism, suspected osteoarticular infection, recent spinal surgery with worsening symptoms, suspected acute vascular pathology, prolonged use of medications or , significant structural spinal deformity, or deterioration of general health.
  • Inability to attend the 3-month follow-up.
  • Poor command of French.
  • Patient under guardianship/curatorship or deprived of liberty.
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
782 participants (estimated)

Study arms

  • No intervention
    Control group

    Usual care - Standard care for acute non-specific low back pain at clinician's discretion

  • Experimental
    Intervention group

    Biopsychosocial approach

    Other: Biopsychosocial intervention

Interventions

  • OtherBiopsychosocial intervention

    The biopsychosocial intervention consists of a structured program implemented in participating emergency departments. It includes a standardized 3-hour online training session for physicians covering evidence-based management of acute low back pain, rational pharmacological use, promotion of physical activity, and consideration of psychosocial factors. A summary sheet will be given with key recommendations during the period. For patients, short educational materials provide information on typical recovery, self-management strategies, and appropriate follow-up. The intervention is introduced sequentially across 12 centers according to a stepped-wedge randomization schedule, with each site moving from control to intervention while maintaining standard emergency care.

06

What researchers measure

Primary outcomes

  1. Pain Interference Score at 7 days

    Pain interference score at 7 days, assessed using the Pain Interference subscale of the Brief Pain Inventory - Short Form (BPI-SF). The score is calculated as the mean of 7 items (each rated 0-10) and reported on a 0-100 scale

    Time frame: 7 days

Secondary outcomes

  1. Pain intensity at 7 days, measured by the BPI SF intensity score.

    Time frame: 7 days

  2. Number of pain-free days after the emergency department visit

    Number of days with BPI intensity at 0

    Time frame: 7 days

  3. Proportion of patients pain free at 7 days

    Time frame: 7 days

  4. Number of days off work

    Number of days off work at 7 days and at 3 months.

    Time frame: 7 days and 3 months.

  5. Functional disability

    Functional disability at 3 months, measured using the Roland-Morris Disability Questionnaire.

    Time frame: 3 months

  6. Patient satisfaction and quality of life

    Patient satisfaction and quality of life at 3 months, assessed using the EQ-5D-5L

    Time frame: 3 months

  7. Number of X-rays, CT scans, and MRI scans of the spine performed

    Time frame: 3 months

  8. Total amount of opioids consumed

    Total amount of opioids consumed at 7 days and at 3 months (in morphine equivalent).

    Time frame: 7 days and 3 months

07

Study locations

1 of 1 sites recruiting
  • Emergency department, Hôpital Pitié Salpêtrière
    Paris, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 12 months is close to that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 29, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Apr 14, 2027
CompletionEst.
Jun 14, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07375914
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Apr 14, 2026
Primary completion
Apr 14, 2027 (estimated)
Completion
Jun 14, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Héloïse BANNELIER, Doctor
Contact
heloise.bannelier@aphp.fr
+ 33 6 48 07 86 23
Yonathan FREUND, Professor
Contact
yonathan.freund@aphp.fr
+33 1 42 17 72 82
Héloïse BANNELIER, Doctor
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion